close

Fundraisings and IPOs

1 64 65 66 67 68 74
Number of results: 1471
Date Company Amount Funding type Investors Therapeutic area Type of Information
2011-12-23 Pharming (The Netherlands) €8.4 million private convertible bond undisclosed institutional investors Rare diseases - Genetic diseases Fundraising
2011-12-23 Tigenix (Belgium) € 2.9 million grant Regenerative medicine Grant
2011-12-22 PTC Therapeutics (UK) $5 million grant The Wellcome Trust (UK) Infectious diseases Grant
2011-12-19 Argen-X (The Netherlands-Belgium) €1.3 million grant Flemish agency for Innovation by Science and Technology (IWT) (Belgium) Cancer - Oncology - Autoimmune diseases Grant
2011-12-19 Cellprothera (France) € 2.5 million financing round R2M (France)- SODIV Alsace (France) Cardiovascular diseases Fundraising
2011-12-19 Atox Bio (Israel) $3.25 million (€2.5 million) financing round Esperante Ventures (UK) Inflammatory diseases Fundraising
2011-12-19 to-BBB (The Netherlands) €600,000 grant Agentschap NL (The Netherlands) Cancer - Oncology - Neurodegenerative diseases - Cardiovascular diseases Grant
2011-12-12 CYTOO (France), Cenix BioScience (Germany), three academic partners €4 million grant European Commission’s Seventh Framework Program (FP7) Technology - Services Grant
2011-12-08 Arcarios (The Netherlands) first tranche of a € 4.5 million loan loan Inflammatory diseases - Rheumatic diseases Establishment of a new subsidiary in the EU
2011-12-08 Verona Pharma (UK) £3.25 million (€3.8 million) private placement Inflammatory diseases - Respiratory diseases Private placement
2011-12-08 ENKAM Pharmaceuticals (Denmark) and Enkam-led consortium, NeuroFGL €6.0 million grant Neurodegenerative diseases Grant
2011-12-08 Agennix (Germany) € 27.5 million capital increase dievini Hopp BioTech  (Germany) - shareholders Cancer - Oncology Capital increase
2011-12-07 EMBL Ventures (Germany) €40 million Subvention
2011-12-06 TopiVert (UK) £8 million (€9.3 million) financing round Inflammatory diseases - Ophtalmological diseases - Allergic diseases - Respiratory diseases Fundraising
2011-12-04 Argen-X (The Netherlands-Belgium) € 32.5 million series B financing round OrbiMed Advisors (USA) - Seventure Partners (France) - Forbion Capital Partners (The Netherlands)- Credit Agricole Private Equity (France) - LSP (the Netherlands-Germany-USA) - BioGeneration Ventures (The Netherlands) - The Erasmus Biomedical Fund (The Netherlands) - Thuja Capital (The Netherlands) - VIB (Belgium) - PMV (Belgium) Autoimmune diseases - Cancer - Oncology Fundraising
2011-12-02 Discuva (UK) undisclosed financing round New Wave Ventures LLP (UK) Infectious diseases Fundraising
2011-12-01 Prosensa (The Netherlands) $1.5 million (€1.18 million) grant Charley’s Fund (USA) Rare diseases - Neuromuscular diseases Grant
2011-11-28 Targovax (Norway) 9 million NOK (€1.1 million) grant Innovation Norway OFU-program (Norway) Cancer - Oncology Grant
2011-11-21 Cytoo (France) €7 million ($10 million) series C financing round Sham (France) - Entrepreneurs Fund (EF)  (France) - AURIGA Partners  (France) - Jacques Lewiner, co-founder and president of the supervisory board at CYTOO.
Technology - Services Fundraising
2011-11-17 Biocartis (Belgium) € 71 million (USD 100 million) Series C equity fund raising Debiopharm Group (Switzerland) - Philips (The Netherlands) - Johnson & Johnson Development Corporation (JJDC) (USA) - the Wellcome Trust (UK) - Korys (investment holding of the Colruyt family) (Belgium)
Valiance
Biovest, the family office of Dr Paul Janssen
IHL SA (Luc Verelst)
PMV
New Rhein Healthcare
certain members of the Biocartis senior management team
the family office of founder Rudi Pauwels (Benaruca).
Infectious diseases Fundraising